a UK-based medtech company that develops blood tests for early cancer detection using proteomics and AI
Oxcan has raised €16M across 3 funding rounds from 16 investors, most recently a Series A round in Jan 2025. Based in Oxford, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-01-10 | Series A | €11M | Angel Investors,Aurelium Ventures,Civilization Ventures,Cross-Border Impact Ventures,DigitalDx Ventures,Eka Ventures+3 more | View deal → |
| 2023-01-10 | Other | €3.5M | Eka Ventures,LifeArc,MegaRobo Technologies,Oxford Technology Management | View deal → |
| 2021-09-06 | Seed | €1.5M | Cancer Research UK,Civilisation Ventures,Francis Crick Institute,MegaRobo,Oxford Technology Management | View deal → |
